Stomach Cancer/Gastric Cancer Treatment Market Size, Share & Industry Analysis, By Drug Type (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, and Others), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST)), By Route of Administration (Oral and Parenteral) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and Regional Forecast, 2021-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Stomach-Gastric- Cancer- Treatment Market with respect to COVID-19 Business Impact.


Inquire before buying

This report focuses on the Stomach-Gastric- Cancer- Treatment market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Stomach-Gastric- Cancer- Treatment market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Stomach-Gastric- Cancer- Treatment Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Stomach-Gastric- Cancer- Treatment Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Stomach-Gastric- Cancer- Treatment Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on to combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Merck & Co., Inc. and F. Hoffmann-La Roche Ltd. to Lead the Market
In terms of stomach cancer treatment market revenue, Merck & Co., Inc. and F. Hoffmann-La Roche Ltd. accounted for the leading position. Approval of Keytruda for gastric cancer in 2017 in the U.S. and Japan increased demand for the drug and this rendered Merck with the maximum share of the market in 2018. On the other hand, Roche accounted for the second position in the market owing to the rising demand for Roches blockbuster drug Herceptin for gastric cancer and also prominent use of Xeloda for chemo treatment.

List Of Key Companies Covered:

 	
Ipsen Pharma
 	
Merck & Co., Inc.
 	
Bristol-Myers Squibb Company
 	
Eli Lilly and Company
 	
F. Hoffmann-La Roche Ltd
 	
Novartis AG
 	
Bayer AG
 	
Celltrion Inc.
 	
TAIHO PHARMACEUTICAL CO., LTD.
 	
Jiangsu Hengrui Medicine Co., Ltd.

REPORT COVERAGE

Stomach cancer is among the most commonly occurring cancer in the world especially in Asia. Owing to its rising prevalence and increasing patient pool, many pharmaceutical companies are making significant investments in the development of novel therapies. Presence of promising pipeline candidates and rapid uptake of targeted and immune therapy is boosting the market.

The gastric cancer treatment market report offers an in-depth analysis of the market. It further provides details on the prevalence of stomach cancer for key countries, regulatory and reimbursement scenario for key countries, new product launches, and key industry developments such as mergers, acquisitions, and partnerships. Information on drivers, opportunities, threats, and restraints of the market can further help stakeholders to gain valuable insights into the market. The report offers a detailed competitive landscape by presenting information on key players, along with their strategies, in the market.

Report Scope & Segmentation

 Segmentation

By Drug Type

 	
Programmed Cell Death Protein 1 (PD-1) Inhibitors
 	
Human Epidermal Growth Factor Receptor (HER2) Antagonists
 	
Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
 	
Others

By Disease Indication

 	
Gastric Adenocarcinoma
 	
Gastrointestinal Stromal Tumor (GIST)
 	
Gastric Neuroendocrine Tumors (gNET)

By Route of Administration

 	
Oral
 	
Parenteral

By Distribution Channel

 	
Hospital Pharmacy
 	
Retail Pharmacy
 	
Online Pharmacy

By Geography

 	
North America (U.S. and Canada)
 	
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
 	
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
 	
Latin America (Brazil, Mexico, and Rest of Latin America)
 	
The Middle East and Africa ( South Africa, GCC, and Rest of the Middle East & Africa)

INDUSTRY DEVELOPMENT:

In October 2020, Blueprint Medicines (Netherlands) B.V. received marketing authorization valid throughout the European Union for Ayvakyt (Avapritinib).  Ayvakyt is a cancer medicine used to treat gastrointestinal stromal tumors (GIST), a cancer of the stomach and bowel, that cannot be removed by surgery and has spread to other parts of the body. Ayvakyt is used when the cancer cells have a D842V mutation, a change in the gene for the platelet-derived growth factor receptor alpha (PDGFRA).  The European Medicines Agency decided that Ayvakyt’s benefits are greater than its risks and it can be authorized for use in the EU.  Ayvakyt benefited a high proportion of patients with GIST with a D842V PDGFRA mutation for a significant length of time. Similar results have not been seen before and are better than those reported in the literature for other medicines of the same type in this patient population, who do not have a lot of treatment options.

Avapritinib or BLU-285,1 is a selective tyrosine kinase inhibitor of KIT and platelet-derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors.2,3 It is one of the first medications available for the treatment of multidrug-resistant cancers. Avapritinib shares a similar mechanism with ripretinib.

In July 2020, Accord Healthcare S.L.U. received marketing authorization valid throughout the European Union for Zercepac(trastuzumab). Zercepac can only be used when cancer overexpresses HER2: this means that cancer produces a protein called HER2 in large quantities on the cancer cells. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
Zercepac has a highly similar structure, purity, and biological activity to Herceptin and is distributed in the body in the same way. In addition, studies in metastatic breast cancer that overexpressed HER2 have shown that the effectiveness of Zercepac infusion is equivalent to that of Herceptin infusion.

In April 2020, Shanghai Henlius Biopharmaceutical Co., Ltd. a wholly-owned subsidiary of the Company, received two Certificates of GMP Compliance of a Manufacturer from Poland’s Chief Pharmaceutical Inspector. The Company’s drug substance (DS) line and drug product (DP) line for HLX02 trastuzumab biosimilar at Xuhui District, Shanghai has successfully passed the Good Manufacturing Practice (GMP) on-site inspection by the EU. In May 2020, the MAA of HLX02 submitted by Accord Healthcare S.L.U. has adopted a positive opinion and recommended approval for MAA from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

November 2019: Pfizer and EMD Serono, Inc. announced positive results from their phase III clinical study on avelumab for the treatment of advanced gastric cancer.

April 2019: Boehringer Ingelheim, a Germany-based company, collaborated with PureTech Health, which will help the company to apply PureTechs lymphatic targeting platform to the companys immuno-oncology candidate for gastric cancer. As a result, the drug can be administrated directly to the gut lymphatics.

March 2019: AstraZeneca entered into a development and commercialization agreement with Daiichi Sankyo, Inc., for trastuzumab deruxtecan, an antibody-drug conjugate under investigation for gastric carcinoma.

September 2017: Keytruda, a PD-1 inhibitor developed by Merck, received FDA approval for the treatment of stomach cancer.